The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to ...
When considering risk modifying treatment in primary prevention, for example treatment for blood pressure, cholesterol or bone density, share the option to have treatment or not before prescribing. Decision aids exist to support this process for doctors and patients.
Provide annual medication reviews for people taking statins.
Use these reviews to discuss medication adherence and lifestyle modification and address CVD risk factors.
Consider an annual nonfasting blood test for non-HDL cholesterol to inform the discussion.
Talk to people who are stable on a low- or medium-intensity statin about the likely benefits and potential risks of switching to a high-intensity statin when they have a medication review, and agree with the person if a change is needed.
Use BMI as a practical measure of overweight and obesity. Interpret it with caution because it is not a direct measure of central adiposity.
In adults with BMI below 35 kg/m2, measure and use their waist-to-height ratio, as well as their BMI, as a practical estimate of central adiposity and use these measurements to help to assess and predict health risks (for example, type 2 diabetes, hypertension or cardiovascular disease).
Use clinical judgement when interpreting the healthy weight category ...
Anticoagulation is potentially harmful and costly. Patients with a first VTE triggered by a major, transient risk factor such as surgery, trauma or an intravascular catheter are at low risk for recurrence once the risk factor has resolved and an adequate treatment regimen with anticoagulation has been completed. Evidence-based and consensus guidelines recommend three months of anticoagulation over shorter or longer periods of anticoagulation in patients with VTE in the setting of a reversible ...